vs

Side-by-side financial comparison of AIRGAIN INC (AIRG) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $12.1M, roughly 1.6× AIRGAIN INC). AIRGAIN INC runs the higher net margin — -20.1% vs -177.4%, a 157.3% gap on every dollar of revenue. On growth, STANDARD BIOTOOLS INC. posted the faster year-over-year revenue change (-11.5% vs -19.6%). AIRGAIN INC produced more free cash flow last quarter ($93.0K vs $-23.1M). Over the past eight quarters, AIRGAIN INC's revenue compounded faster (-7.7% CAGR vs -12.2%).

Airgain Inc is a leading provider of high-performance wireless connectivity solutions, including advanced antenna products, embedded radio modules, and custom connectivity systems. It serves core market segments such as IoT, automotive, smart home, enterprise networking, and telecommunications, delivering reliable high-speed wireless performance for various connected device use cases.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

AIRG vs LAB — Head-to-Head

Bigger by revenue
LAB
LAB
1.6× larger
LAB
$19.6M
$12.1M
AIRG
Growing faster (revenue YoY)
LAB
LAB
+8.1% gap
LAB
-11.5%
-19.6%
AIRG
Higher net margin
AIRG
AIRG
157.3% more per $
AIRG
-20.1%
-177.4%
LAB
More free cash flow
AIRG
AIRG
$23.2M more FCF
AIRG
$93.0K
$-23.1M
LAB
Faster 2-yr revenue CAGR
AIRG
AIRG
Annualised
AIRG
-7.7%
-12.2%
LAB

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
AIRG
AIRG
LAB
LAB
Revenue
$12.1M
$19.6M
Net Profit
$-2.4M
$-34.7M
Gross Margin
44.8%
48.5%
Operating Margin
-20.0%
-168.5%
Net Margin
-20.1%
-177.4%
Revenue YoY
-19.6%
-11.5%
Net Profit YoY
-24.4%
-28.8%
EPS (diluted)
$-0.21
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AIRG
AIRG
LAB
LAB
Q4 25
$12.1M
Q3 25
$14.0M
$19.6M
Q2 25
$13.6M
$21.8M
Q1 25
$12.0M
$40.8M
Q4 24
$15.1M
Q3 24
$16.1M
$22.1M
Q2 24
$15.2M
$22.5M
Q1 24
$14.2M
$45.5M
Net Profit
AIRG
AIRG
LAB
LAB
Q4 25
$-2.4M
Q3 25
$-964.0K
$-34.7M
Q2 25
$-1.5M
$-33.5M
Q1 25
$-1.5M
$-26.0M
Q4 24
$-2.0M
Q3 24
$-1.8M
$-26.9M
Q2 24
$-2.5M
$-45.7M
Q1 24
$-2.5M
$-32.2M
Gross Margin
AIRG
AIRG
LAB
LAB
Q4 25
44.8%
Q3 25
43.6%
48.5%
Q2 25
42.9%
48.8%
Q1 25
43.0%
48.4%
Q4 24
42.2%
Q3 24
41.7%
54.9%
Q2 24
40.5%
46.1%
Q1 24
39.2%
53.1%
Operating Margin
AIRG
AIRG
LAB
LAB
Q4 25
-20.0%
Q3 25
-6.9%
-168.5%
Q2 25
-14.7%
-118.1%
Q1 25
-25.8%
-80.8%
Q4 24
-13.1%
Q3 24
-11.3%
-120.9%
Q2 24
-16.5%
-134.5%
Q1 24
-18.5%
-132.2%
Net Margin
AIRG
AIRG
LAB
LAB
Q4 25
-20.1%
Q3 25
-6.9%
-177.4%
Q2 25
-10.8%
-153.7%
Q1 25
-12.9%
-63.8%
Q4 24
-13.0%
Q3 24
-10.9%
-122.0%
Q2 24
-16.6%
-203.3%
Q1 24
-17.3%
-70.6%
EPS (diluted)
AIRG
AIRG
LAB
LAB
Q4 25
$-0.21
Q3 25
$-0.08
$-0.09
Q2 25
$-0.12
$-0.09
Q1 25
$-0.13
$-0.07
Q4 24
$-0.17
Q3 24
$-0.16
$-0.07
Q2 24
$-0.23
$-0.12
Q1 24
$-0.23
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AIRG
AIRG
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$7.4M
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$28.3M
$399.7M
Total Assets
$45.3M
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AIRG
AIRG
LAB
LAB
Q4 25
$7.4M
Q3 25
$7.1M
$129.4M
Q2 25
$7.7M
$158.6M
Q1 25
$7.4M
$150.9M
Q4 24
$8.5M
Q3 24
$7.3M
$210.6M
Q2 24
$8.4M
$269.8M
Q1 24
$7.2M
$287.1M
Total Debt
AIRG
AIRG
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
AIRG
AIRG
LAB
LAB
Q4 25
$28.3M
Q3 25
$29.7M
$399.7M
Q2 25
$29.8M
$424.5M
Q1 25
$30.3M
$454.6M
Q4 24
$31.0M
Q3 24
$30.8M
$489.3M
Q2 24
$31.6M
$510.3M
Q1 24
$30.5M
$577.3M
Total Assets
AIRG
AIRG
LAB
LAB
Q4 25
$45.3M
Q3 25
$45.5M
$539.6M
Q2 25
$45.5M
$557.0M
Q1 25
$46.1M
$579.6M
Q4 24
$48.4M
Q3 24
$43.3M
$681.5M
Q2 24
$42.4M
$708.7M
Q1 24
$42.8M
$777.7M
Debt / Equity
AIRG
AIRG
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AIRG
AIRG
LAB
LAB
Operating Cash FlowLast quarter
$194.0K
$-22.2M
Free Cash FlowOCF − Capex
$93.0K
$-23.1M
FCF MarginFCF / Revenue
0.8%
-118.1%
Capex IntensityCapex / Revenue
0.8%
4.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-1.3M
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AIRG
AIRG
LAB
LAB
Q4 25
$194.0K
Q3 25
$-411.0K
$-22.2M
Q2 25
$129.0K
$-20.7M
Q1 25
$-1.0M
$-30.3M
Q4 24
$-26.0K
Q3 24
$-1.2M
$-27.9M
Q2 24
$-1.2M
$-39.0M
Q1 24
$-1.1M
$-62.5M
Free Cash Flow
AIRG
AIRG
LAB
LAB
Q4 25
$93.0K
Q3 25
$-418.0K
$-23.1M
Q2 25
$113.0K
$-22.6M
Q1 25
$-1.1M
$-35.3M
Q4 24
$-27.0K
Q3 24
$-1.2M
$-30.1M
Q2 24
$-1.3M
$-41.0M
Q1 24
$-1.2M
$-63.3M
FCF Margin
AIRG
AIRG
LAB
LAB
Q4 25
0.8%
Q3 25
-3.0%
-118.1%
Q2 25
0.8%
-103.6%
Q1 25
-8.9%
-86.6%
Q4 24
-0.2%
Q3 24
-7.5%
-136.4%
Q2 24
-8.5%
-182.2%
Q1 24
-8.3%
-138.9%
Capex Intensity
AIRG
AIRG
LAB
LAB
Q4 25
0.8%
Q3 25
0.0%
4.5%
Q2 25
0.1%
8.7%
Q1 25
0.3%
12.4%
Q4 24
0.0%
Q3 24
0.2%
10.2%
Q2 24
0.6%
8.6%
Q1 24
0.4%
1.7%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AIRG
AIRG

Transferred At Point In Time$11.3M93%
Other$803.0K7%

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons